Vactech employs its proprietary IMAVAC™ virus‑like particle platform to produce PRV‑101, a multivalent Coxsackie B vaccine that blocks the viral trigger of type 1 diabetes, and paired diagnostic assays that detect early enterovirus exposure. The company licenses these preventive immunotherapies and companion diagnostics to pharmaceutical and biotech partners for T1D and other enterovirus‑related conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Type 1 diabetes (T1D) develops when enterovirus infections, particularly Coxsackie B viruses, trigger an autoimmune attack on pancreatic β‑cells. Current care is limited to lifelong insulin therapy, and there are no preventive vaccines or reliable early‑diagnostic tools to identify at‑risk individuals.
Solution
Vactech leverages its proprietary IMAVAC™ virus‑like particle (VLP) platform to create a multivalent vaccine (PRV‑101) that safely mimics Coxsackie B serotypes and elicits strong neutralising antibody responses without using live virus. The vaccine is designed to block the enteroviral trigger, thereby preventing the onset of T1D in genetically susceptible populations. In parallel, Vactech has patented diagnostic assays that detect enterovirus exposure early, enabling risk‑based intervention. The same VLP technology underpins additional candidates for celiac disease and other enterovirus‑related conditions, providing a unified pipeline of preventive immunotherapies and companion diagnostics.
Target Audience
Primary customers are pharmaceutical and biotech partners seeking licensed preventive vaccines and diagnostic kits for T1D and related enterovirus diseases, as well as clinical research programs focused on early‑intervention strategies for at‑risk pediatric populations.
Features
- IMAVAC™ VLP platform: recombinant, non‑infectious particles that present native viral epitopes, delivering robust immunogenicity comparable to traditional vaccines.
- PRV‑101 multivalent formulation: targets the most prevalent Coxsackie B serotypes linked to T1D, demonstrated safety and immunogenicity in a double‑blind Phase I trial.
- Patent‑protected portfolio covering vaccine composition, antiviral drug candidates, and diagnostic assays for enterovirus‑associated diseases.
- Early‑detection diagnostics: highly specific assays for enterovirus RNA/protein that identify at‑risk individuals before autoimmunity develops.
- Scalable manufacturing process using ion‑exchange chromatography and GMP‑compatible expression systems, facilitating rapid up‑scaling for global distribution.
- Broad disease applicability: the platform can be adapted to vaccines for celiac disease and other enterovirus‑related pathologies (e.g., myocarditis, meningitis).